Moderna stock jumps 110% on first positive Phase 3 cancer vaccine

Moderna’s stock (MRNA) rose more than 110% after reporting the first positive Phase 3 results for a personalized cancer vaccine. The milestone signals market confidence in mRNA therapeutics beyond infectious disease: increased risk appetite for biotech could spill over to risk assets, including growth equities and select crypto sectors correlated with tech sentiment.